Publications by authors named "N Georgoulia"
Article Synopsis
- The AEGEAN trial showed that combining durvalumab with chemotherapy improved treatment outcomes for patients with operable non-small cell lung cancer (NSCLC) compared to chemotherapy alone.
- The MDT-BRIDGE study is investigating neoadjuvant durvalumab plus chemotherapy in patients with stage IIB-IIIB NSCLC to assess their resectability and treatment outcomes post-surgery or chemoradiotherapy.
- The study aims to evaluate the effectiveness of the treatment based on various factors including surgery rates, event-free survival, and safety profiles, with a focus on patients transitioning from resectable to unresectable status.
Background: We wanted to evaluate if event-free survival (EFS) is a reliable surrogate for overall survival (OS) in patients with resectable non-small cell lung cancer (r-NSCLC) receiving neoadjuvant therapy. We conducted a systematic literature review and meta-analysis to investigate the statistical association between EFS and OS.
Research Design And Methods: Electronic databases were searched on 30 July 2021 to identify sources reporting both EFS and OS data in patients with stage I-IIIB r-NSCLC receiving neoadjuvant therapy.
Purpose: Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus-exemestane (E/E) is an established effective treatment in hormone receptor-positive/HER2-negative mBC patients. The effect of E/E on CTCs in mBC patients was prospectively investigated.
Methods: CTCs from 50 pre-treated patients with mBC receiving E/E were analyzed using the CellSearch (CS) platform and triple immunofluorescence (IF) staining for cytokeratin, M30 and Ki67 expression to assess their proliferative and apoptotic status.
Article Synopsis
- The study aimed to examine the presence of Bcl-2 positive circulating tumor cells (CTCs) in small cell lung cancer (SCLC) patients who hadn't undergone chemotherapy and their significance during initial treatment.
- Researchers collected peripheral blood from 66 patients at various treatment stages and used techniques like CellSearch and immunofluorescence to detect CTCs.
- The findings revealed that a significant percentage of patients had detectable CTCs before treatment, with a notable decrease after one treatment cycle; however, CTC levels increased at relapse, highlighting their potential as dynamic biomarkers for patient outcomes.
Purpose: Τo evaluate the clinical relevance of CEACAM5mRNA-positive circulating tumor cells (CTCs) in patients with metastatic colorectal cancer (mCRC).
Methods: Peripheral blood was obtained from 436 patients with mCRC before the initiation of systemic therapy. A second sample was obtained on treatment assessment from 296 (67.